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Summary Introduction: Tibial nerve entrapment is highly prevalent in diabetic subjects, re- 
sulting in significantly more neuropathic complaints and concomitant sensory disturbances. The 
study aim was to assess the impact of tarsal tunnel syndrome (TTS) and sensory loss at baseline 
on incident diabetic foot ulceration (DFU) in diabetic patients, since decompressing the tibial 
nerve might change the natural history of the disease. 
Methods: In this study, 113 subjects with TTS (69 bilateral, 23 left-sided and 21 right-sided) 
participating in the prospective Rotterdam Diabetic Foot Study were compared to 303 diabetic 
controls without TTS, regarding incident DFU. Kaplan–Meier analysis and Cox’s regression anal- 
ysis were used to determine the independent hazard of baseline variables for new DFU. 
Results: The median observation period was 836.5 days (IQR, 459–1077.8). In bilateral TTS, 
17.4% (95% CI: 8.4–26.3%) of subjects experienced DFU versus 8.3% (95% CI: 5.1–11.6%) in con- 
trols (left or right) during follow-up ( p = 0.0036). In left-sided TTS, no subjects versus 6.2% 
(95% CI: 3.4–9.0%) in controls had DFUs ( p = 0.243). Incident ulceration was seen in 14.3% (95% 
CI: −0.7% to −29.3%) of right-sided TTS subjects versus 4.1% (95% CI: 1.5–6.3%) in controls 
( p = 0.034). Besides HbA1c, diminished sensation at the hallux independently increased the 
Dates and sites of presentation: Portions of this work were presented at the 2019 Annual Meetings of the American Society for Peripheral 
Nerve in Palm Desert, CA, USA, January 2019. 
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risk of ulceration, in patients with (HR: 4.692, p = 0.003) and without (HR: 2.307, p = 0.002) 
prior DFU. 
Discussion: Elevated sensory thresholds in TTS render diabetic patients at a higher risk for DFU. 
With effective surgery, TTS is likely to be an amenable factor to potentially prevent diabetic 
foot disease and thereby reduce amputation risk. 
Level of evidence: II. 
© 2020 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by El- 
sevier Ltd. All rights reserved. 
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ntroduction 
ibial nerve entrapment at the tarsal tunnel was first re-
orted in 1962, when Keck described a patient with anes- 
hesia over the sensory distribution of the tibial nerve with
ocalized tenderness and paresthesias of the foot sole when 
apping the nerve posterior to the medial malleolus. 1 Since 
hen multiple reports have been published on diagnostic cri- 
eria, including the physical examination, electrodiagnostic 
tudies, and imaging, together with studies on treatment 
odalities, which are mainly surgical. 2-4 In the 1980s, di- 
betic patients were identified for having higher rates of 
arsal tunnel syndrome (TTS), as diabetes predisposes the 
eripheral nerve to chronic compression (i.e. the double 
rush syndrome). 5 , 6 Only a few studies have been published 
elated to the beneficial effects of a tibial nerve release,
hese effects include relief of complaints, gain of sensory 
unction, and prevention of lower extremity ulcers and am- 
utations. 7-14 
TTS is a more common condition of the foot and an-
le than has been historically appreciated in the litera- 
ure, but no studies exist on its natural history. Therefore,
he prospective and observational Rotterdam Diabetic Foot 
RDF) Study was initiated to investigate the natural course 
f tibial nerve entrapment in diabetic subjects. A previous 
ross-sectional analysis of baseline RDF study measurements 
as shown that TTS in diabetic subjects is prevalent and ac-
ompanied by significantly higher plantar cutaneous thresh- 
lds and significantly more neuropathic symptoms. 4 The aim 
f the current study was to investigate the degree to which
ensory deficits observed in uni- and bilateral TTS in dia-
etic subjects result in an increased risk of diabetic foot
lceration (DFU) compared to those without signs of tibial 
erve entrapment. 
ethods 
tudy design and subjects 
he RDF study is a prospective cohort study of unselected di-
betic patients followed at the outpatient Diabetes Clinic of 
ranciscus Gasthuis and Vlietland, Rotterdam, the Nether- 
ands. The aim of the RDF study was to investigate the nat-
ral history of neuropathy, including deterioration of sen- 
ation of the feet. The RDF study participants were re-
ruited from patients visiting the specialized outpatient di- 
betes clinic. RDF study inclusion criteria were: type 1 or
ype 2 diabetes mellitus (treated by oral blood glucose- owering drugs and/or insulin), age over 18 years, no sig-
ificant cognitive impairment, speaking Dutch, and signed 
nformed consent. Exclusion criteria were: active radicular 
yndrome and neurological disease interfering with sensi- 
ility of the feet, as reported in the interview and screen-
ng questionnaire. The RDF study design and methods have
een described in detail. 4 , 15 Baseline measurements were 
arried out between January 2014 and June 2015, for which
atients were subjected to an interview, to a physical ex-
mination and were requested to fill in a questionnaire (on
moking history, neuropathic symptoms, and history of foot 
r leg ulcer and amputation), which was repeated during the
ollow-up visits with 1–1.5 years’ intervals. Demographic, 
nthropometric, and care data (e.g., weight, length, blood 
ressure, diabetes type, duration, and treatment), and lab- 
ratory results were retrieved from the patient file. The
edical Research Ethics Research Committee of Erasmus MC 
edical University Center, Rotterdam, the Netherlands, ap- 
roved the study (MEC-2009-148). 
hysical examination: the Rotterdam Diabetic Foot 
tudy Test Battery 
oth feet were examined. Static- and moving two-point 
iscrimination (S2PD and M2PD) were tested with a Disk-
riminator TM (from 2 to 15 mm) (US Neurologicals, LLC,
oulsbo, WA, USA). Static one-point discrimination (S1PD) 
as tested with a set of Semmes-Weinstein monofilaments 
from 0.008 to 300 g) (Baseline® Tactile TM , Minneapolis, MN,
SA). S2PD, M2PD and S1PD test sites were chosen in agree-
ent with the nerve territories of the foot: I, plantar hallux
medial plantar nerve [tibial nerve]); II, medial heel (cal-
aneal nerve [tibial nerve]); III, first dorsal web (deep per-
neal nerve); IV, lateral foot (sural nerve); and V, plantar
fth toe (lateral planter nerve [tibial nerve]). M2PD was 
ot tested at the fifth toe due to its small surface area.
ibration sense was tested with a Rydel-Seiffer tuning fork
scored from 0 to 8) (Martin, Tuttlingen, Germany) at the
edial malleolus and dorsal interphalangeal joint of the hal-
ux. Neuropathy symptoms were assessed using the Michigan 
europathy Screening Instrument (MNSI), which was admin- 
stered before the physical examination. Sensory test items 
onsisted of both a sensory test and test location (e.g., S1PD
t the lateral foot [S1PD IV], S2PD at the plantar fifth toe
S2PD V]). Lower extremity artery pulsations were palpated 
or each foot separately. TTS was diagnosed at study base-
ine when both a positive Tinel sign at the tarsal tunnel
nd neuropathic complaints were present, according to a 
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previous study. 4 Patients were categorized in 1) bilateral
TTS, 2) unilateral TTS (right), 3) unilateral TTS (left), and
4) diabetic patients without TTS. 
Data collection 
Demographic (age, sex, medical history), anthropometric
(height, weight, body mass index), and lower limb sensory
status information (full RDF Study Test Battery) was col-
lected at RDF study baseline and follow-up visit one (Jan-
uary 2015 to October 2016) and two (March 2017 to July
2017). Data on incident DFU was collected half-yearly us-
ing telephone call follow-up and included the circumstances
of each ulcer (e.g. side, date), usage of medical resources
and the need for hospitalization. The reporting standards of
studies on the prevention and management of foot ulcers in
diabetes are followed. 16 
Statistical analysis 
Shapiro-Wilk tests were used to assess the normality of con-
tinuous data. Differences between groups were assessed us-
ing Kruskal-Wallis tests. A subscore on nerve-related neuro-
pathic MNSI items is reported for the three groups 4 . Crude
estimates of ulcer incidence rates in the different groups
were calculated as the total number of cases with DFUs,
divided by the total number of subjects in the respec-
tive groups. Confidence intervals (CIs) were obtained as
95% binomial confidence intervals. The Kaplan–Meier anal-
ysis was conducted to compare the time to DFU of bilat-
eral and unilateral (left and right) TTS in diabetic patients
to those without TTS, in terms of DFU development. Inci-
dence of ulceration was considered an event. A log rank
test was conducted to determine whether there were dif-
ferences in the distributions for the different groups. The
Kaplan–Meier curves were not adjusted for covariates. Cox
proportional hazards models were fit to identify indepen-
dent predictors of DFU development, in which RDF study
subjects with TTS were compared with subjects without
TTS. Potential predictor variables were chosen on the ba-
sis of 1) current literature; 2) expert opinion, and 3) avail-
ability in the RDF study dataset. Since sensory measure-
ments correlated highly, only monofilament (S1PD) mea-
surements of both halluces were included in the mod-
els. A univariate model was fitted that included the base-
line measurement variables only. A multivariable adjusted
model included all exposure variables, and the final ad-
justed model was determined using backward stepwise
(likelihood ratio) reduction, maintaining all univariate ex-
posure variables with p < 0.10, in 20 iterations. Differ-
ences were expressed in unadjusted and adjusted hazard
ratios (HR) with 95% CIs. Since previous DFU was an in-
teraction variable, Kaplan–Meier curves are depicted that
show the differences in occurrence according to the de-
gree of sensory loss (S1PD). Two curves were plotted sep-
arately for patients with and without a previous DFU. Sta-
tistical analysis was carried out using IBM SPSS Statistics
version 24.0 (IBM Corp., Armonk, New York, USA). We con-
sidered p values below 0.05 (two-sided) to be statistically
significant. Results 
Patient characteristics 
At baseline, 69 diabetic patients with a median age of
62.7 years (interquartile range (IQR), 52.6–69.6) had bi-
lateral TTS and 44 patients (65.2 years (IQR, 55.1–71.3))
had unilateral TTS (prevalence: 17.7% (95% CI: 13.9–21.5)
vs. 29.9% (25.2–34.5%)). 4 The remaining RDF study partici-
pants without TTS served as controls ( n = 303). Groups were
comparable regarding the majority of demographic data,
but patients with bilateral TTS had a higher body weight
( p = 0.005), had more often retinopathy ( p = 0.032), and on
average higher HbA1c levels ( p = 0.016) at study entry com-
pared to the other groups ( Table 1 , Baseline data). During
RDF study follow-up, 32 patients withdrew from study par-
ticipation, 66 patients were lost to follow-up and 22 pa-
tients died. 
Limb-level characteristics 
Table 2 shows that more severe sensory deficit was ob-
served in TTS patients compared to controls, in the form
of higher cutaneous thresholds (S1PD, all parameters:
p < 0.001), impaired spatial discrimination (S2PD, all pa-
rameters: p ≤ 0.004 and M2PD, all parameters: p ≤ 0.009),
and a more frequent history of ulceration ( p = 0.021). The
cutaneous threshold (S1PD) frequently surpassed the critical
limit of 10 g in the majority of tibial nerve innervated test
locations in both bilateral and left-sided TTS patients, but
generally not in right-sided patients, compared to controls.
Left-sided TTS patients had fewer palpable lower extrem-
ity arteries compared to the other groups, but this did not
reach statistical significance. Bilateral and unilateral TTS
patients had significantly more neuropathic symptoms com-
pared to controls ( p < 0.0005). Fifty-two participants had a
history of ulceration and 14 participants a prior amputation
due to previous DFU disease (before study entry). 
Incidence of ulceration 
During follow-up, 48 episodes of ulceration were registered,
in 40 participants. The rate of new-onset ulceration from
study start was 9.6% (95% CI: 7.0-12.9%) in a median ob-
servation period of 836.5 days (IQR, 459–1077.8). A total of
65 ulcers occurred, with nine patients developing multiple
DFU episodes in the period of observation. An average num-
ber of 1.3 DFUs were observed per episode. The majority of
patients presented with ulcer(s) at toes two to five (43.1%),
followed by DFUs at the hallux (38.5%). A minority suffered
from ulcers at the heel (9.2%), plantar-side of the metatar-
sophalangeal joints (3.1%), and plantar-side of the midfoot
(1.5%), and in 3 patients (4.6%), these data were not avail-
able. 
Ulcer-related outcomes in tarsal tunnel syndrome 
In bilateral affected TTS patients ( n = 69), 12 ulcers (17.4%,
95% CI: 9.3–28.4%) occurred (left or right), compared to 23
ulcers (8.7%, 95% CI: 5.6–12.7%) in control subjects ( n = 265)
during a median follow-up of 824 days (IQR, 487–1098.5).
Figure 1 shows the distributions for the bilateral, unilat-
eral (left), and unilateral (right) TTS groups compared to
controls. A log rank test showed statistically significantly
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Table 1 Baseline data. 
Bilateral TTS Unilateral TTS Other RDF-study 
participants 
P -value 
Subjects (n) 69 44 303 
Gender (M/F) 25/44 20/24 130/173 0.097 ∗
Age (median (y), IQR) 62.7 (52.6–69.6) 65.2 (55.1–71.3) 64.0 (55.2–69.9) 0.645 # 
Ethnicity (n (%)) 0.669 ∗
- Caucasian 58 (84.1) 40 (90.9) 243 (80.2) 
- Indo-Surinamese 5 (7.2) 1 (2.3) 29 (9.6) 
- African 1 (1.4) 2 (4.5) 11 (3.6) 
- Asian 1 (1.4) – 6 (2.0) 
- Other 4 (5.8) 1 (2.3) 14 (4.6) 
Height (median (m), IQR) 178.0 (167.5–183.0) 175.0 (164.3–180.8) 172.0 
(165.0–180.0) 
0.272 # 
Weight (median (kg), IQR) 94.6 (82.5–112.2) 86.1 (75.3–99.9) 86.8 (76.0–102.0) 0.005 # 
BMI (median (kg/m 2 ), IQR) 31.4 (26.9–35.3) 29.1 (25.7–32.6) 29.0 (25.8–33.4) 0.053 # 
Duration of diabetes (median (y), IQR) 18.0 (8.5–27.5) 17.0 (9.3–26.0) 16.0 (9.0–24.0) 0.688 # 
Type of diabetes (n (%)) 0.980 ∗
- Type 1 16 (23.2) 10 (22.7) 67 (22.1) 
- Type 2 53 (76.8) 34 (77.3) 236 (77.9) 
Insulin use (n (%)) 59 (85.5) 37 (84.1) 255 (63.1) 0.961 ∗
Systolic blood pressure (median mmHg, IQR) 140.0 (126.5–150.0) 135.5 (124.8–144.5) 136.0 
(125.0–147.0) 
0.518 # 
Diastolic blood pressure (median mmHg, IQR) 80.0 (69.5–85.0) 75.5 (69.0–80.0) 77.0 (70.0–82.0) 0.587 # 
Retinopathy (n (%)) 19 (40.4) 5 (22.7) 42 (22.0) 0.032 ∗
Lifetime smoking history (n (%)) 42 (73.7) 23 (67.6) 121 (60.5) 0.167 ∗
Laboratory measurements 
HbA1c (median (mmol/L), IQR) 63.0 (55.0–74.5) 61.0 (54.0–75.0) 59.0 (51.0–68.0) 0.016 # 
MDRD (median ml/ min /1.73 m 2 , IQR) 77.1 (57.7–100.8) 77.0 (51.6–100.6) 79.1 (61.1–95.7) 0.948 # 
Total cholesterol (median (mmol/L), IQR) 4.2 (3.6–5.0) 4.3 (3.5–4.6) 4.0 (3.5–4.8) 0.931 # 
LDL-C (median (mmol/L), IQR) 1.9 (1.4–2.7) 1.7 (1.3–2.4) 1.8 (1.4–2.5) 0.631 # 
HDL-C (median (mmol/L), IQR) 1.3 (1.1–1.6) 1.3 (1.1–1.6) 1.3 (1.1–1.7) 0.363 # 
TG (median (mmol/L), IQR) 1.5 (1.0–2.5) 1.8 (1.1–2.7) 1.5 (1.0–2.3) 0.272 # 
ApoB (median (g/L), IQR) 0.9 (0.8–1.1) 0.9 (0.8–1.2) 0.9 (0.8–1.1) 0.659 # 
Microalbumin (median (mg/L), IQR) 21.0 (8.0–72.0) 15.5 (8.0–41.0) 16.5 (8.0–54.3) 0.672 # 
∗, Pearson-Chi Square statistic; #, Kruskal-Wallis test; TTS, tarsal tunnel syndrome; M, male; F, female; IQR, interquartile range; BMI, 
body mass index; HbA1c, glycated hemoglobin; MDRD, Modification of Diet in Renal Disease; LDL, low density lipoprotein; HDL, high 
density lipoprotein; TG, triglycerides; ApoB, apolipoprotein B; RDF, Rotterdam Diabetic Foot. 
Figure 1 Kaplan–Meier curves of tarsal tunnel syndrome in diabetic subjects. 
TTS, tarsal tunnel syndrome. 
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a  ifferent distributions, X 2 (1) = 4.418, p = 0.036. Unilat-
ral affected patients had a median follow-up of 839 days 
IQR, 454–1077). In left-sided affected patients ( n = 23),
o ulcers occurred in the left foot, compared to 18 ul-
ers (6.2%, 95% CI: 3.7–9.6%) in controls ( n = 290). The
istributions were not statistically significantly different 
X 2 (1) = 1.366, p = 0.243). In right-sided affected patients
 n = 21), three ulcers (14.3%, 95% CI: 3.0–36.3%) occurredn the right foot, compared to 12 ulcers (4.1%, 95% CI: 2.1–
.0%) in controls ( n = 294). A log rank test showed statis-
ically significantly different distributions (X 2 (1) = 4.479, 
 = 0.034). 
ox-regression analysis 
able 3 shows the results of the univariate and multivari-
ble Cox proportional hazards models, comparing the risk of
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Table 2 Limb-level measurements. 
Bilateral tarsal 
tunnel syndrome 
( n = 69) 
Left-sided tarsal 
tunnel syndrome 
( n = 23) 
Right-sided tarsal 
tunnel syndrome 
( n = 21) 
Other RDF-study 
participants 
( n = 303) 
P -value 
Limb sensory status 
Static one-point discrimination ♦ (median g (IQR)) 
- Left hallux 4.0 (1.4–100.0) 6.0 (2.0–180.0) 2.0 (0.6–10.0) 2.0 (0.6–6.0) < 0.0005 # 
- Left medial heel 4.0 (1.4–15.0) 15.0 (1.4–60.0) 2.0 (0.6–8.0) 2.0 (0.6–8.0) < 0.0005 # 
- Left fifth toe 4.0 (1.4–26.0) 2.0 (1.0–60.0) 2.0 (1.2–4.9) 1.4 (0.6–4.0) < 0.0005 # 
- Right hallux 4.9 (1.4–88.0) 6.0 (2.0–180.0) 2.0 (1.0–10.0) 1.4 (0.6–8.0) < 0.0005 # 
- Right medial heel 6.0 (1.4–26.0) 8.0 (1.4–60.0) 2.0 (0.8–11.0) 2.0 (0.6–8.0) 0.001 # 
- Right fifth toe 4.0 (1.0–26.0) 2.0 (1.0–60.0) 2.0 (0.8–4.0) 1.4 (0.6–4.0) < 0.0005 # 
Static two-point discrimination ♦ (median mm (IQR)) 
- Left hallux 16.0 (11.3–16.0) 16.0 (11.0–16.0) 13.0 (8.0–16.0) 11.0 (8.0–16.0) < 0.0005 # 
- Left medial heel 16.0 (12.0–16.0) 16.0 (10.0–16.0) 16.0 (12.0–16.0) 14.0 (8.0–16.0) 0.004 # 
- Left fifth toe 16.0 (15.0–16.0) 15.0 (10.0–16.0) 16.0 (9.5–16.0) 12.0 (7.0–16.0) < 0.0005 # 
- Right hallux 16.0 (12.0–16.0) 15.0 (9.0–16.0) 11.0 (6.5–16.0) 11.0 (7.0–16.0) 0.001 # 
- Right medial heel 16.0 (12.3–16.0) 16.0 (7.0–16.0) 16.0 (11.5–16.0) 13.0 (8.0–16.0) 0.001 # 
- Right fifth toe 16.0 (11.5–16.0) 16.0 (9.0–16.0) 16.0 (11.5–16.0) 12.0 (7.0–16.0) < 0.0005 # 
Moving two-point discrimination ♦ (median mm (IQR)) 
- Left hallux 12.5 (8.0–16.0) 11.5 (8.0–16.0) 12.0 (8.0–16.0) 8.0 (5.0–14.0) < 0.0005 # 
- Left medial heel 12.0 (7.0–16.0) 14.0 (8.0–16.0) 15.0 (10.5–16.0) 9.0 (6.0–15.0) 0.009 # 
- Right hallux 12.0 (9.0–16.0) 10.5 (6.5–16.0) 10.0 (6.0–16.0) 8.0 (5.0–14.8) < 0.0005 # 
- Right medial heel 13.0 (7.8–16.0) 14.0 (8.0–16.0) 13.0 (7.5–16.0) 9.0 (5.0–15.0) 0.004 # 
Vibration sense (median (IQR)) 
- Left interphalangeal joint 4.0 (1.0–5.5) 3.0 (0.0–6.0) 4.0 (3.0–6.5) 4.0 (2.0–6.0) 0.157 # 
- Right interphalangeal joint 4.0 (0.0–5.0) 4.0 (0.0–4.0) 4.0 (2.5–6.0) 4.0 (2.0–6.0) 0.049 # 
Michigan Neuropathy Screening Instrument 
Neuropathic symptoms (median 
score (IQR)) 
2.0 (1.0–3.0) 1.0 (1.0–3.0) 2.0 (1.0–2.0) 0.0 (0.0–2.0) < 0.0005 # 
Vascular limb status 
Previous diabetic foot 
ulceration (n%)) 
16 (23.2) 4 (17.4) 2 (9.5) 30 (9.9) 0.021 ∗
Previous amputations (n (%)) 
- Left extremity 0 1 (4.3) 0 5 (1.7) 0.428 ∗
- Right extremity 2 (2.9) 0 0 6 (2.0) 0.749 ∗
Palpable lower extremity arteries (%) 
- Left posterior tibial artery 74.2 60.0 73.7 71.7 0.661 ∗
- Left dorsalis pedis artery 73.8 70.0 84.2 75.8 0.749 ∗
- Right posterior tibial artery 66.7 60.0 65.0 71.5 0.888 ∗
- Right dorsalis pedis artery 69.7 65.0 80.0 71.7 0.948 ∗
♦ , S1PD, S2PD and M2PD are censored data. Only on tibial nerve innervated areas is reported. ∗, Pearson-Chi Square statistic # , Kruskal- 
Wallis test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ulceration in combined bilateral and unilateral TTS patients
to controls. In unadjusted analyses, baseline measurements
of the following characteristics were significantly associated
with ulcer risk: male sex, retinopathy, diminished one-point
discrimination (i.e. monofilaments), non-palpable lower ex-
tremity arteries, prior foot ulcer, prior amputation, and
HbA1c. In adjusted analyses, diminished one-point discrim-
ination at the right hallux, prior ulcer, and HbA1c were as-
sociated with an increased risk of ulceration, while a lower
risk of ulceration was seen with a lower systolic blood pres-
sure. 
The hazard ratio of prior ulceration in the whole group
was 2.40 (CI: 1.11-5.19), p = 0.026. In the group of pa-
tients with prior ulceration, this was 4.69 (CI: 1.69–13.01),
p = 0.003, in the group without prior ulceration this was2.31 (CI: 1.36–3.90), p = 0.002. Figure 2 shows the resultant
Kaplan–Meier curves. 
Discussion 
This study showed that the natural history of TTS in a dia-
betic patient has a positive predictive value for the devel-
opment of DFU. In a large prospective cohort of adults with
diabetes, a higher risk for DFU development was found in
patients with TTS, in both bilateral and right-sided affected
patients. Diagnosis-specific multivariable analysis showed a
more important role for prior DFU, the level of HbA1C at
inclusion, and increased sensory thresholds. With regard to
abnormal sensory thresholds, multivariable analysis showed
The natural history of tarsal tunnel syndrome in diabetic subjects 1487 
Table 3 Unadjusted and adjusted hazard ratios for incident diabetic foot ulceration among diabetic patients. 
HR (95%CI), unadjusted P-value HR (95%CI), adjusted P-value 
Male sex 2.614 (1.191–5.737) 0.017 
Age (years) 1.015 (0.986 –1.044) 0.326 
Duration of diabetes (years) 1.012 (0.987 –1.038) 0.333 
Diabetes type 2 1.287 (0.564 –2.939) 0.549 
Insulin use 0.850 (0.354 –2.042) 0.716 
BMI (kg/m 2 ) 0.992 (0.938 –1.048) 0.768 
Systolic blood pressure (mmHg) 1.001 (0.984 –1.018) 0.909 0.967 (0.928 –1.007) 0.108 
Lifetime smoking history 0.817 (0.383 –1.746) 0.603 
Retinopathy 3.400 (1.381–8.368) 0.008 
Tarsal tunnel syndrome 1.711 (0.876 –3.344) 0.116 
Static one-point discrimination 
- Left hallux 3.390 (2.378–4.832) < 0.0005 
- Right hallux 4.137 (2.810–6.092) < 0.0005 2.401 (1.111–5.189) 0.026 
Palpable lower extremity arteries 
- Left posterior tibial artery 0.235 (0.119–0.463) < 0.0005 
- Left dorsalis pedis artery 0.392 (0.202–0.761) 0.006 
- Right posterior tibial artery 0.274 (0.141–0.531) < 0.0005 
- Right dorsalis pedis artery 0.455 (0.236–0.879) 0.019 
Previous diabetic foot ulceration 17.005 (8.679–33.316) < 0.0005 9.786 (2.387–40.127) 0.002 
Previous diabetes-related amputation 9.852 (3.766–25.774) < 0.0005 
HbA1c (mmol/L) 1.024 (1.002–1.046) 0.032 1.038 (1.002–1.076) 0.037 
MDRD (ml/ min /1.73 m 2 ) 0.994 (0.982 –1.007) 0.381 
HR, hazard ratio; statistically significant results appear in boldface type ( p < 0.05); BMI, body mass index; HbA1c, glycated 
hemoglobin; MDRD, Modification of Diet in Renal Disease. 
Figure 2 Kaplan–Meier curves of diabetic subjects with (left panel) and without (right panel) prior ulceration, according to the 
degree of sensory loss. 
S1PD measurements are categorized according to hallux measurements (Group 0: 0 ≤ 10 g, Group 1: > 10 ≤ 100 g and Group 2: 
> 100 g). 
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o  hat the degree of sensory loss was significantly associated 
ith the risk of ulceration, independent of the signs of tibial
erve entrapment at baseline. In our opinion, these findings 
ay have important consequences for patient selection for 
arsal tunnel decompression. 
The results from our data support a complex etiology of
FU that includes both person- and limb-level factors. 17 As 
roposed earlier from baseline RDF study measurements, 
he increased sensory thresholds observed in tibial nerve 
ompression relates to the risk of ulceration. 4 In fact, neu-
opathy, in the form of sensory deafferation, is arguably 
he most important risk factor in the cascade to ulcer de-
elopment in persons with and without prior DFU. The as- 
ociated hazard ratio was of the highest magnitude in thedjusted Cox proportional hazards analysis, with symptoms 
f TTS being surpassed by this hazard. Prior ulceration was
ssociated with re-ulceration, and therefore, the foot in 
hich wound closure is achieved should be regarded as in
emission, rather than being healed. 17 , 18 Since the diagnos- 
ic limitation of self-reported symptoms is acknowledged, 
e conclude that the more objective somatosensory exami- 
ation is key in accessing the risk of ulceration and may also
erve in the decision when to decompress the tarsal tunnel
n the natural history of tibial nerve entrapment. Current
iterature suggests a dramatic improvement in spatial acu- 
ty and cutaneous pressure thresholds after tarsal tunnel 
elease in diabetic subjects, with studies reporting post- 
perative sensory thresholds of 0.5–0.8 g, coming from 32.9
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to 65.6 g pre-operatively. 7 , 8 , 10 , 12 This type of surgery may
therefore change the natural history of neuropathy in dia-
betes, since re-innervation of the foot sole may reverse the
associated hazards of the insensate foot. 11 , 19 If surgical de-
compression is to be performed, the timing of the surgery is
an important factor for optimizing the operative result. 20 
Patients are generally operated when having positive (hy-
peralgesia, allodynia) or negative (hypoesthesia, hypoalge-
sia) symptoms of neuropathy, together with a positive Tinel
sign or positive provocative testing at the site of compres-
sion. 2 The decision to decompress the tarsal tunnel depends
on the physical examination, since electrodiagnostic test-
ing does not aid to the diagnosis of TTS due to the high
percentage of asymptomatic people who have abnormal
sensory and motor results. 21 , 22 In all stages of neuropathy
the Tinel sign may be present, of which processes of de-
and remyelinization lie at root. 23 , 24 Relief of pressure suf-
ficiently soon restores nerve function, with blood flowing
in the altered neurovascular structures, after decompres-
sion. 25 An optimal timing of surgery has not yet been es-
tablished, but should include consideration of complaints,
quality of life, and the increased sensory thresholds at the
plantar side of the foot. 10 , 26 Somatosensory function pre-
sumably correlates with the likelihood of nerve regenera-
tion. 20 Since a cutaneous threshold of ≥10 g is a significant
predictor of future ulceration and surpasses the normative
cutaneous threshold of the feet exceedingly, lower values
should probably be availed, supplemented with other sen-
sory measurements, when surgery is specifically planned to
prevent lower extremity complications. 27 A recent grading
scale of somatosensory function of the feet may aid this de-
bate. 15 , 20 , 23 Interestingly, recent reports on lower extremity
nerve decompression (LEND) showed that nerve outgrowth
could also be expected from patients with end-stage neu-
ropathy, reversing the chance of ulcer recurrence. 12 , 28 , 29 
To date, the RDF study is the only observational cohort
study to determine the prognostic value of tibial nerve com-
pression in diabetic subjects in light of risk of ulcer devel-
opment. An additional important finding is that the associ-
ated degree of sensory loss is the most important hazard
in both patients with and without prior ulceration. How-
ever, our study had a number of limitations. First, the RDF
cohort is a hospital-based cohort, with patients at higher
risk of lower extremity complications compared to the gen-
eral diabetes population. The incidence rate of DFUs for
the whole cohort was comparable with the literature and
slightly higher compared to the numbers seen in primary
care, as expected. 30 However, only relatively low absolute
numbers of new DFUs were seen in the TTS groups, due
to sample size limitations, but still with significant differ-
ences. In fact, no new ulcers were observed in the 23 unilat-
eral left-sided affected limbs, resulting in a non-significant
trend in this time frame, compared to controls. Our hypoth-
esis was nonetheless confirmed in the 69 bilateral and 21
right-sided affected patients and may also be confirmed in
left-sided patients when a longer follow-up is available. The
generalizability of our findings remains to be determined.
Second, no complete data were available on the type or
severity of foot deformations, which is considered a risk
factor for foot ulceration. 17 , 31 Third, in the adjusted anal-
ysis, palpable pulses in the lower limbs were not selected,
although previous studies found associations between thesemeasurements and new DFU and/or amputation. 32 , 33 A com-
bination of tests is recommended to more reliably exclude
peripheral artery disease. 34 Finally, potential confounders
of this multivariable analysis cannot be ignored, with new
ulcers being influenced by risk factors not measured at base-
line. Examples include compliance with foot care, health-
care provision, and patient-factors such as kidney disease.
Also we do not know if the condition spontaneously resolves
or inexorably progresses to foot ulceration. Our cohort of
416 diabetic subjects represents the most detailed assess-
ment of plantar sensory function in the light of tibial nerve
pathology, together with a unique 3.5-year follow-up assess-
ment of DFU development in non-operated patients with
TTS. Our data seem representative; since the baseline de-
mographic characteristics of our population and reports on
TTS characteristics are comparable with other teaching hos-
pitals and with data from the literature. 12 , 35 
In conclusion, we have demonstrated that patients with
TTS are at higher risk of foot ulceration due to the ob-
served increased cutaneous thresholds at study baseline.
Bilateral affected patients do worse compared to unilat-
eral patients and controls, and are at higher risk of DFU de-
velopment than unilateral patients. Furthermore, we have
now elucidated the natural history of TTS in diabetic sub-
jects, for which surgical interventions may help change its
course into DFU development. 12 , 36 , 37 High expediency is an-
ticipated from re-innervating the insensate foot, making
this type of surgery a promising therapy to battle the in-
creasingly burdensome and expensive DFU pandemic. 38 , 39 
Although controversy towards LEND surgery continues to ex-
ist, our study provides the necessary evidence to progress to
high-quality data. 40 
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